InvestLog
IMA ImageneBio Inc logo

IMA ImageneBio Inc

Healthcare
$5.56+0.72%ClosedMarket Cap: $62.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.51

P/S

0.00

EV/EBITDA

0.10

DCF Value

$4.99

FCF Yield

-83.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-35.2%

ROA

-33.0%

ROIC

-42.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-10.6M$—
Q4 null$0.00$-6.9M$—
FY null$800.0K$-45.3M$—
Q3 null$0.00$-24.8M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$1.33

Target (Median)

$1.33

Target Range

$1.33 - $1.33

0 Strong Buy2 Buy0 Hold1 Sell0 Strong Sell
WedbushUnderperform
2026-05-11
WedbushNeutral
2025-07-25

Trading Activity

Insider Trades

View All
Lally Robert Bofficer: Principal Accounting Officer
SellMon Apr 20
Lally Robert Bofficer: Principal Accounting Officer
SellMon Apr 20
Su Wei-guo
SellThu Apr 16
ORBIMED ADVISORS LLCdirector
BuyThu Apr 16
ORBIMED ADVISORS LLCdirector
BuyThu Apr 16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.74

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

Peers

ARTV logoARTVCNTB logoCNTBCNTX logoCNTXIFRX logoIFRXKLRS logoKLRSMGX logoMGXOVID logoOVIDQNCX logoQNCXSTRO logoSTROSTTK logoSTTK